The Memory Clinic

Bennington, Vermont 05201-9810

2 studies enrolling now · 40 studies all time

What they study most

Agitation Associated With Alzheimer's Disease Dementia, Alzheimer Disease, Alzheimer Disease (AD), Alzheimer's Disease, Alzheimers Disease, Alzheimer´s Disease, Behavioral Variant Frontotemporal Dementia (bvFTD), Central Nervous System Diseases, Cognition, Cognitive Impairment, Dementia, Frontotemporal Dementia

Studies at this site

• A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1) — Recruiting now
• Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia — Recruiting now
• A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease — Completed
• Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder — Completed
• A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ) — Completed
• A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3) — Running, not enrolling
• A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) — Running, not enrolling
• A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease — Stopped early
• A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 — Stopped early
• A Study of Semorinemab in Patients With Moderate Alzheimer's Disease — Completed
• An Observational Study of Aducanumab-avwa in Participants With Alzheimer's Disease in the US — Stopped early
• A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease — Completed
• A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease — Stopped early
• BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease. — Completed
• Tau Screening Study in Patients With Early Symptomatic AD — Completed
• EEG/ERP Longitudinal Study in Alzheimer's Disease (AD) — Completed
• An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease — Stopped early
• A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia — Stopped early
• A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease — Stopped early
• Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo — Stopped early
• BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease. — Completed
• Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD) — Completed
• Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab — Stopped early
• Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients — Stopped early
• A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease — Stopped early
• Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease — Completed
• Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients — Stopped early
• Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease — Completed
• DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease — Completed
• Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease — Completed
• Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease. — Completed
• A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease — Stopped early
• Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier) — Completed
• Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier) — Completed
• Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44 — Completed
• An Evaluation of the Safety and Efficacy of Memantine in Agitated Patients With Moderate to Severe Alzheimer's Disease — Completed
• A Study of PRX-03140 in Subjects With Alzheimer's Disease Receiving a Stable Dose of Donepezil — Stopped early
• Study of PRX-03140 Monotherapy in Subjects With Alzheimer's Disease — Stopped early
• 18-Month Study of the Efficacy of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type — Completed
• Evaluation of 3APS in Patients With Mild to Moderate Alzheimer's Disease — Status unconfirmed